Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM-RCA-01 in Metastatic Cancers Expressing FGFR1
NCT07292168Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OM-RCA-001 in renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), head and neck cancer (HNC) and 2 more. Primary endpoints: Primary endpoint in the phase 1b study at 6 months and Primary endpoint in the phase 2 study at 12 months. Started Dec 2025; status: recruiting.
02
Drugs
OM-RCA-001
03
Conditions
renal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)head and neck cancer (HNC)breast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT07292168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07292168.